Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody

Journal of Controlled Release

Volumn 120, Issue 1-2, 2007, Pages 18-26

  Kocbek, Petra ^a   Obermajer, Nataša ^a   Cegnar, Mateja ^a   Kos, Janko ^a   Kristl, Julijana ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Active targeting; Cell co culture; Monoclonal antibody; Nanoparticles; PLGA

Indexed keywords

CELL CULTURE; MONOCLONAL ANTIBODIES; NANOPARTICLES; ONCOLOGY; ORGANIC ACIDS; SURFACE PLASMON RESONANCE;

CANCER CELLS; POLYLACTIC-CO-GLYCOLIC ACID (PLGA) IMMUNO-NANOPARTICLES; RECOGNITION PROPERTIES;

TUMORS;

MONOCLONAL ANTIBODY; NANOPARTICLE; POLYGLACTIN;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DRUG ADSORPTION; DRUG FORMULATION; DRUG TARGETING; DRUG UPTAKE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CACO-2 CELLS; CELL MEMBRANE; COCULTURE TECHNIQUES; DRUG CARRIERS; FEMALE; FLOW CYTOMETRY; FLUORESCEIN; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUORESCENT DYES; HUMANS; KERATINS; LACTIC ACID; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; POLYGLYCOLIC ACID; POLYMERS; SURFACE PLASMON RESONANCE;

EID: 34249894977     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2007.03.012     Document Type: Article

References (36)

1. Petrak K. Essential properties of drug-targeting delivery systems. Drug Discov. Today 10 23-24 (2005) 1667-1673
2. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 5517 (1975) 495-497
3. Garnett M.C. Targeted drug conjugates: principles and progress. Adv. Drug Del. Rev. 53 2 (2001) 171-216
4. Funaro A., Horenstein A.L., Santoro P., Cinti C., Gregorini A., and Malavasi F. Monoclonal antibodies and therapy of human cancers. Biotechnol. Adv. 18 5 (2000) 385-401
5. Trail P.A., and Bianchi A.B. Monoclonal antibody drug conjugates in the treatment of cancer. Curr. Opin. Immunol. 11 5 (1999) 584-588
6. Trail P.A., King H.D., and Dubowchik G.M. Monoclonal antibody drug immunoconjugates. Cancer Immunol. Immunother. 52 5 (2003) 328-337
7. Lambert J.M. Drug-conjugated monoclonal antibodies for treatment of cancer. Curr. Opin. Pharmacol. 5 5 (2005) 543-549
8. Fahmy T.M., Fong P.M., Goyal A., and Saltzman W.M. Targeted for drug delivery. Mater. Today 8 8 (2005) 18-26
9. Sapra P., and Allen T.M. Ligand-targeted liposomal anticancer drug. Prog. Lipid Res. 42 5 (2003) 439-462
10. Jaracz S., Chen J., Kuznetsova L.V., and Ojima I. Recent advances in tumour-targeting anticancer drug conjugates. Bio. Med. Chem. 13 17 (2005) 5043-5054
11. Nobs L., Buchegger F., Gurny R., and Allémann E. Current methods for attaching targeting ligands to liposomes and nanoparticles. J. Pharm. Sci. 93 8 (2004) 1980-1988
12. Dinauer N., Balthasar S., Weber C., Kreuter J., Langer K., and von Briesen H. Selective targeting of antibody-conjugated nanoparticles to leucemic cells and primary T-lymphocytes. Biomaterials 26 29 (2005) 5898-5906
13. Panyam J., and Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Del. Rev. 55 3 (2003) 329-347
14. Stella B., Arpicco S., Peracchia M.T., Desmaële D., Hoebeke J., Renoir M., D'Angelo J., Cattel L., and Couvreur P. Design of folic acid-conjugated nanoparticles for drug targeting. J. Pharm. Sci. 89 11 (2000) 1452-1464
15. Vasir J.K., Reddy M.K., and Labhasetwar V.D. Nanosystems in drug targeting: opportunities and challenges. Curr. Nanosci. 1 1 (2005) 47-64
16. Cegnar M., Premzl A., Zavašnik - Bergant V., Kristl J., and Kos J. Poly(lactide-co-glicolide) nanoparticles as a carrier system for delivering cysteine protease inhibitor cystatin into tumor cells. Exp. Cell Res. 301 2 (2004) 223-231
17. Beketic-Oreskovic L., Sarcevic B., Malenica B., and Novak D.J. Immunocytochemical reactivity of a mouse monoclonal antibody CDI315B raised against human breast carcinoma. Neoplasma 40 (1993) 69
18. Cegnar M., Kos J., and Kristl J. Cystatin incorporated in poly(lactide-co-glycolide) nanoparticles: development and fundamental studies on preservation of its activity. Eur. J. Pharm. Sci. 22 5 (2004) 357-364
19. Hermanson G.T. Bioconjugate Techniques, I (1996), Academic Press, London 169-172
20. Hjelm H., Hjelm K., and Sjoquist J. Protein A from Staphylococcus aureus. Its isolation by affinity chromatography and its use as an immunosorbent for isolation of immunoglobulins. FEBS Lett. 28 1 (1972) 73-76
21. Cegnar M., Kristl J., and Kos J. Nanoscale polymer carriers to deliver chemotherapeutic agents to tumours. Exp. Opin. Biol. Ther. 5 12 (2005) 1557-1569
22. L. Juillerat-Jeanneret, F. Schmitt, Chemical modification of therapeutic drugs or drug vector systems to achieve targeted therapy: looking for the grail, Med. Res. Rev. (in press).
23. Steinhauser I., Spänkuch B., Strebhardt K., and Langer K. Transtuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials 27 28 (2006) 4975-4983
24. Cirstoiu-Hapca A., Bossy-Nobs L., Buchegger F., Gurny R., and Delie F. Differential tumor cell targeting of anti-HER2 Herceptin®) and anti-CD20 (Mabthera®) coupled nanoparticles. Int. J. Pharm. 331 2 (2007) 190-196
25. Illum L., Jones P.D.E., Kreuter J., Baldwin R.W., and Davis S.S. Adsorption of monoclonal antibodies to polyhexylcyanoacrylate nanoparticles and subsequent immunospecific binding to tumour cells in vitro. Int. J. Pharm. 17 1 (1983) 65-76
26. Barbet J., Machy P., and Leserman L. Monoclonal covalently coupled to liposomes: specific targeting to cells. J. Supramol. Struct. Cell. Biochem. 16 3 (1981) 243-258
27. 14C]methacrylate nanoparticles after intravenous injection in rats. J. Pharm. Sci. 73 10 (1984) 1433-1437
28. Tsai T., Mehta R.C., and DeLuca P.P. Adsorption of peptides to poly(d,l-lactide-co-glycolide): 2. Effect of solution properties on the adsorption. Int. J. Pharm. 127 1 (1996) 43-52
29. Roskos K.V., and Maskiewicz R. In: Sanders L.M., and Hendren R.W. (Eds). Degradable Controlled Release Systems Useful for Protein Delivery. Protein delivery: Physical Systems vol. 10 (1997), Plenum Press, New York 45-92
30. Torchilin V.P. Drug targeting. Eur. J. Pharm. Sci. 11 Suppl. 2 (2000) S81-S91
31. Davda J., and Labhasetwar V. Characterization of nanoparticle uptake by endothelial cells. Int. J. Pharm. 233 1-2 (2002) 51-59
32. Sahoo S.K., Panyam J., Prabha S., and Labhasetwar V. Residual polyvinyl alcohol associated with poly(d,l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Control. Release 82 1 (2002) 105-114
33. Panyam J., and Labhasetwar V. Dynamics of endocytosis and exocytosis of poly(d,l-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm. Res. 20 2 (2003) 212-220
34. Lynch I. Are there generic mechanisms governing interactions between nanoparticles and cells? Epitope mapping the outher layer of the protein-material interface. Physica, A Stat. Ther. Phys. 373 (2007) 511-520
35. Rowland R.E.S., Taylor P.W., and Florence A.T. Attachment, uptake and transport of nanoparticles coated with an internalin A fragment in Caco-2 cell monolayer. J. Drug Del. Sci. Technol. 15 4 (2005) 313-317
36. Park J.S., Han T.H., Lee K.Y., Han S.S., Hwang J.J., Moon D.H., Kim S.Y., and Cho Y.W. N-acetyl histidine-conjugated glycol chitosan self-assembled nanoparticles for intracytoplasmic delivery of drugs: endocytosis, exocytosis and drug release. J. Control. Release 115 1 (2006) 37-45